Activation of SHP-1 protein shows benefit in IPF mouse model

Activation of SHP-1 protein shows benefit in IPF mouse model

Treatment with a molecule designed to activate the SHP-1 protein led to prolonged survival and alleviation of disease-associated lung changes in a mouse model of idiopathic pulmonary fibrosis (IPF), a study found. SHP-1 activation appeared to exert its protective effects by inhibiting the survival and pro-fibrotic activity of a…

Insilico’s AI-designed molecule enters Phase 2 testing

Insilico Medicine made its entry into Phase 2 clinical testing with INS018_055, a small molecule it discovered and designed using artificial intelligence (AI), as a potential treatment for idiopathic pulmonary fibrosis (IPF). Patients have now received the first dose of oral INS018_055 in a randomized placebo-controlled Phase 2…

How I’ve overcome adversity on my IPF journey

Adversity is something rare disease patients face on a regular basis. It can take many forms, but it often involves facing a challenging situation or doing something against all odds. When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, I don’t think I had any…

Learning the ins and outs of palliative care for PF patients

What choices do you have when you have idiopathic pulmonary fibrosis (IPF) and lung transplant isn’t an option? I’ve been told by more than one patient that they were told to go home and spend the time they have left enjoying a rocking chair on the porch. Whether that is actually what they…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums